| Species |
Mouse |
| Protein Construction |
TGF-β2 (Ala303-Ser414)
Accession # P27090 |
|
| Purity |
> 95% as analyzed by SDS-PAGE |
| Endotoxin Level |
< 1 EU/μg of protein by LAL method |
| Biological Activity |
ED50 < 0.2 ng/ml, measured in a cell proliferation assay using mouse HT-2 cells. |
| Expression System |
Human Cells |
| Apparent Molecular Weight |
~12.7 kDa, on SDS-PAGE under reducing conditions. |
| Formulation |
Lyophilized from a 0.2 μm filtered solution in 4 mM HCl. |
| Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in 4 mM HCl to 100 μg/mL. |
| Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Transforming growth factor beta 2 (TGF-β2) is a member of TGF-beta superfamily that shares a characteristic cysteine knot structure. Mice with TGF-β2 gene deletion show defects in development of cardiac, lung, craniofacial, limb, spinal column, eye, inner ear and urogenital systems. All TGF-β isoforms signal via the same heteromeric receptor complex, consisting of a ligand binding TGF-β receptor type II (TβR-II), and a TGF-β receptor type I (TβR-I). Signal transduction from the receptor to the nucleus is mediated via SMADs. TGF-β expression is found in cartilage, bone, teeth, muscle, heart, blood vessels, hematopoietic cells, lung, kidney, gut, liver, eye, ear, skin, and the nervous system. |
| Synonyms |
Transforming growth factor beta-2; TGFB2; Polyergin; G-TSF; Glioblastoma-derived T-cell suppressor factor; Cetermin; BSC-1 cell growth inhibitor; TGF-beta-2 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
